Drug Trial Radar · NCT01533532
A Randomized, Placebo-controlled, Double-blind Study of KLH-2109 in Patients With Endometriosis (2)
Last checked: Nov 19, 2026Latest source record: May 30, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 15, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- Female only, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of KLH-2109 in patients with endometriosis.
Conditions
- Endometriosis
Interventions
KLH-2109Drug
KLH-2109Drug
KLH-2109Drug
placeboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The severity score of the pelvic painTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Japan
Tokyo and Other Japanese City, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.